中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2010年
10期
1322-1323
,共2页
胃肿瘤%多西他赛%顺铂%氟尿嘧啶%抗肿瘤联合化疗方案
胃腫瘤%多西他賽%順鉑%氟尿嘧啶%抗腫瘤聯閤化療方案
위종류%다서타새%순박%불뇨밀정%항종류연합화료방안
Stomach neoplasms%Docetaxel%Cisplatin%Fluorouracil%Antineoplastic combined chemotherapy protocols
目的 探讨多西他赛联合顺铂和氟尿嘧啶治疗进展期胃癌的疗效和毒副反应.方法 35例经病理确诊的进展期胃癌应用多西他赛、顺铂(DDP)、氟尿嘧啶(5-Fu)化疗,其中多西他赛70 mg/m2静滴4 h,第1天;DDP 20 mg/m2静滴d 1～d 5;5-Fu 750 mg/m2静滴6 h,d 1～d 5,每3～4周重复.化疗有效者至少4～6个疗程或一直治疗至疾病进展(PD)为止.结果 有32例(91.4%)患者可以评价客观疗效,其中完全缓解(CR)0,部分缓解(PR)15例,稳定(SD)7例,进展(PD)10例.总缓解(CR+PR)率46.9%(15/32),CR率为0,SD率为21.9%(7/32).骨髓抑制主要表现为WBC下降,发生率为40.0%,其中Ⅲ～Ⅳ度者占13.6%,有1例发生发热性粒细胞减少,经积极处理好转,未见严重的全身感染和治疗相关死亡.结论 多西他赛联合顺铂和氟尿嘧啶方案是治疗进展期胃癌的有效方案,毒副反应可耐受,临床使用安全.
目的 探討多西他賽聯閤順鉑和氟尿嘧啶治療進展期胃癌的療效和毒副反應.方法 35例經病理確診的進展期胃癌應用多西他賽、順鉑(DDP)、氟尿嘧啶(5-Fu)化療,其中多西他賽70 mg/m2靜滴4 h,第1天;DDP 20 mg/m2靜滴d 1～d 5;5-Fu 750 mg/m2靜滴6 h,d 1～d 5,每3～4週重複.化療有效者至少4～6箇療程或一直治療至疾病進展(PD)為止.結果 有32例(91.4%)患者可以評價客觀療效,其中完全緩解(CR)0,部分緩解(PR)15例,穩定(SD)7例,進展(PD)10例.總緩解(CR+PR)率46.9%(15/32),CR率為0,SD率為21.9%(7/32).骨髓抑製主要錶現為WBC下降,髮生率為40.0%,其中Ⅲ～Ⅳ度者佔13.6%,有1例髮生髮熱性粒細胞減少,經積極處理好轉,未見嚴重的全身感染和治療相關死亡.結論 多西他賽聯閤順鉑和氟尿嘧啶方案是治療進展期胃癌的有效方案,毒副反應可耐受,臨床使用安全.
목적 탐토다서타새연합순박화불뇨밀정치료진전기위암적료효화독부반응.방법 35례경병리학진적진전기위암응용다서타새、순박(DDP)、불뇨밀정(5-Fu)화료,기중다서타새70 mg/m2정적4 h,제1천;DDP 20 mg/m2정적d 1～d 5;5-Fu 750 mg/m2정적6 h,d 1～d 5,매3～4주중복.화료유효자지소4～6개료정혹일직치료지질병진전(PD)위지.결과 유32례(91.4%)환자가이평개객관료효,기중완전완해(CR)0,부분완해(PR)15례,은정(SD)7례,진전(PD)10례.총완해(CR+PR)솔46.9%(15/32),CR솔위0,SD솔위21.9%(7/32).골수억제주요표현위WBC하강,발생솔위40.0%,기중Ⅲ～Ⅳ도자점13.6%,유1례발생발열성립세포감소,경적겁처리호전,미견엄중적전신감염화치료상관사망.결론 다서타새연합순박화불뇨밀정방안시치료진전기위암적유효방안,독부반응가내수,림상사용안전.
Objective To evaluate the efficacy and toxicity of docetaxel combined with Cisplatin(DDP) and 5-fluorouracil(5-Fu) in the treatment of advanced gastric cancer. Methods 35 patients with advanced gastric cancer,which were confirmed by pathological diagnosis,were treated with docetaxel + DDP +5-Fu regimen:docetaxel 70 mg/m2 iv infusion for 4 hours on day 1, DDP 20 mg/m2 iv infusion on day 1 to 5,5-Fu 750 mg/m2 iv infusion for 6 hours on day 1 to 5 every 3 ～ 4weeks. Patients responsing to the chemotherapy finished at least 4 ～ 6 cycles or proceeded the therapy until progression of the disease (PD). Results 32 cases (91.4% ) were available for response evaluation with CR0;PR 15;SD7;PD 10. The rate of total remission( CR + PR) was 46.9% (15/32) ,and rates of CR and SD were 0 and 21.9% respectively. Leucopenia was seen in 40% patients,in which 13.6% cases were in grade III -IV. One patient had fever with neutropenia and improved after active treatment. There was no systemic infection or therapy-related death in all patients. Conclusion Docetaxel + DDP +5-Fu regimen has an assured response for advanced gastric cancer with tolerable toxicity and could be an effective candidate in clinical treatment.
